Werewolf Therapeutics Reports Promising Clinical Data for Cancer Immunotherapies, Advances T Cell Engager Pipeline
核心洞察
Werewolf Therapeutics' WTX-124 demonstrated a 30% overall response rate as monotherapy in post-immunotherapy advanced melanoma patients with favorable tolerability profile.
WTX-330 Phase 1b/2 trial showed additional evidence of antitumor activity and highly favorable tolerability, including a confirmed partial response in metastatic gallbladder cancer (搜索).
The company announced two new INDUCER T cell engager candidates, WTX-1011 (搜索) targeting STEAP1 (搜索) and WTX-2022 (搜索) targeting CDH6 (搜索), with IND filings planned for mid-2027.
Werewolf Therapeutics announced compelling clinical data for its INDUKINE immunotherapy programs and significant progress in its INDUCER T cell engager platform, positioning the company for potential regulatory advancement in cancer treatment.
WTX-124 Shows Strong Activity in Refractory Melanoma
The company's lead candidate WTX-124, a conditionally activated interleukin-2 (IL-2) molecule, demonstrated notable efficacy in heavily pretreated melanoma patients. In the Phase 1/1b clinical trial, WTX-124 achieved a 21% objective response rate as monotherapy in patients with advanced or metastatic cutaneous melanoma (搜索), consistent with historic high-dose IL-2 activity.
More significantly, among melanoma patients who had previously responded to immunotherapy (non-primary resistant patients), WTX-124 achieved a 30% objective response rate. The treatment showed activity across multiple tumor types, with approximately 33% of patients treated with 12 or 18 mg doses experiencing tumor regression in renal cell carcinoma (搜索), cutaneous squamous cell carcinoma (搜索), non-small cell lung cancer (搜索), and other solid tumors.
The safety profile proved favorable, with no evidence of vascular leak syndrome or recurrence of prior immune-related adverse events. Grade 3 and 4 treatment-related adverse events occurred in 25.5% and 1.9% of patients, respectively, based on data from 106 patients as of October 20, 2025.
FDA Provides Regulatory Guidance
At a recent End of Phase 1 meeting, the FDA accepted 18 mg as the recommended dose for WTX-124's continued development and provided initial guidance for a monotherapy registration path in post-immunotherapy advanced or metastatic relapsed/refractory melanoma.
"We are encouraged by the unprecedented clinical responses in conjunction with tolerability demonstrated by WTX-124 as a monotherapy and in combination with pembrolizumab in patients with cancers refractory to standard of care," said Dan Hicklin, PhD, President and CEO of Werewolf.
WTX-330 Demonstrates Improved Profile
WTX-330, the company's conditionally activated interleukin-12 (搜索) (IL-12) candidate, showed additional evidence of antitumor activity in its Phase 1b/2 trial. An optimized manufacturing process improved the safety profile, pharmacokinetics, and therapeutic index compared to earlier studies.
At a dose of 0.024 mg/kg administered intravenously every two weeks, WTX-330 achieved a 17-fold higher maximum concentration (Cmax) than published data for recombinant human IL-12, while maintaining free IL-12 levels at only 0.12% of prodrug exposure across all dose levels.
As of December 2, 2025, the trial documented one confirmed partial response in metastatic gallbladder cancer (搜索) that had failed prior standard of care, with a 45% reduction in tumor target lesions according to RECIST 1.1 criteria.
INDUCER Platform Advances with Dual Candidates
Werewolf announced significant progress in its INDUCER T cell engager platform, revealing a second development candidate alongside the previously disclosed WTX-1011 (搜索). The new candidate, WTX-2022 (搜索), targets the CDH6 (搜索) tumor-associated antigen for ovarian and kidney cancers, while WTX-1011 targets STEAP1 (搜索) for prostate cancer (搜索).
Preclinical data for both candidates demonstrated robust silencing, reversible masking, and highly efficient activation in human tumor tissue. The studies showed potent antitumor activity in murine models of human tumor xenografts and excellent prevention of cytokine release in initial non-human primate studies.
The INDUCER molecules utilize the same proprietary masking approach and novel linker technology clinically validated in the WTX-124 and WTX-330 programs. Cell line development has been initiated for both programs, with IND-enabling studies underway and IND filings planned for mid-2027, pending additional funding.
Strategic Partnerships and Future Development
The company is actively seeking strategic partnerships for further development of its INDUKINE programs. Additional Phase 1/1b data updates for WTX-124 and completion of Part A of the Phase 1b/2 clinical trial for WTX-330 are both expected in the first half of 2026.
Werewolf's approach focuses on conditionally activated molecules that remain inactive in peripheral tissue but activate selectively in the tumor microenvironment, addressing limitations of conventional proinflammatory immune therapies. The company believes these qualities could establish it as a leading T cell engager company by improving therapeutic index and reducing off-tumor toxicity.